Open letters
Table of contents
- Reply in follow up to the COVI exchange of views on 27 March 2023
- Reply to open letter from Members of the European Parliament's letter on psychedelic-assisted therapies
- Reply to open letter from Members of the European Parliament concerning COVID-19 vaccines
- Reply to open letter from ‘Doctors for COVID ethics’ concerning COVID-19 vaccines
- Reply to open letter concerning COVID-19 vaccines
- Letter from the chairs of EMA's Management Board to Guido Rasi at the end of his term as EMA's Executive Director
- Reply to open letter concerning the transparency and evaluation of vaccines for COVID-19
- Response to the European Ombudsman concerning transparency and independence of EMA's work in supporting the development and evaluation of COVID-19 medicines
- Response to the Institute for Quality and Efficiency in Health Care (IQWiG) and the Cochrane Collaboration on transparency of COVID-19-related activities
- Rapid response to the British Medical Journal on Pandemrix
- Response to European Ombudsman regarding pre-submission activities
- Response to Nordic Cochrane Centre on safety review of human papillomavirus vaccines
- Clarifying the adaptive pathways concept
- Response to European Ombudsman explaining redaction rules
- Response to European Ombudsman on clinical trial data transparency
- Letter to Member of European Parliament requesting correction
- Response to British Medical Journal editorial on the new Agency
The European Medicines Agency (EMA) publishes open letters, usually in response to contributions and feedback from stakeholders.
Reply in follow up to the COVI exchange of views on 27 March 2023
Reply to open letter from Members of the European Parliament's letter on psychedelic-assisted therapies
Reply to open letter from Members of the European Parliament concerning COVID-19 vaccines
Reply to open letter from ‘Doctors for COVID ethics’ concerning COVID-19 vaccines
Reply to open letter concerning COVID-19 vaccines
Reply to open letter concerning the transparency and evaluation of vaccines for COVID-19
-
List item
European Medicines Agency second response to European Ombudsman regarding pre-submission activities (PDF/174.5 KB)
First published: 26/11/2019
EMA/627113/2019 -
List item
European Medicines Agency first response to European Ombudsman regarding pre-submission activities (PDF/165.74 KB)
First published: 20/09/2017
Last updated: 20/09/2017
EMA/566402/2017
-
List item
EMA response to Nordic Cochrane letter on human papillomavirus (HPV) vaccines - Conflict of interest issues of Executive Director (PDF/74.72 KB)
First published: 22/07/2016
Last updated: 22/07/2016 -
List item
EMA response to Nordic Cochrane letter on EMA response to Nordic Cochrane letter on human papillomavirus (HPV) vaccines - Maladministration (PDF/198.13 KB)
First published: 22/07/2016
Last updated: 22/07/2016